

Report Title	Integrated Quality & Performance Report April 2020		
Sponsoring Executive	Dave Baker, Director of Partnerships and Innovation		
Report Author	Yasmina Gainer, Head of Performance and Costing		
Meeting	Trust Board (Public)	Date	04 June 2020

1. Suggested discussion points *[two or three issues you consider the Board should focus on]*

In April we observed the impact of the COVID-19 on a full month basis. With regards to responsiveness, our performance change follows what is happening on the national scale i.e. A&E attendances decline but 4 hour performance improves, RTT backlog rising, diagnostic (DMO1) performance dropping and patient numbers generally falling away. Our response to this is our recovery plan. Beyond this:

- We have achieved the Cancer 62-day standard for all four quarters in 2019/2020.
- The treatment of positively diagnosed Sepsis within 1 hour stays below or at 60% for the fifth consecutive month. Work is underway to understand why this is happening.
- There were seven 52 week breaches, all impacted by the cancellation of elective operations due to Covid 19.
- Administration errors around intended management are causing the initial performance of VTE assessment to under report. After validation we achieved 94.9% against the 95% standard. Further administration errors are believed to be the cause of readmissions spiking to 9.7%. Work is under way to resolve both these issues.
- CLE provided assurance that low performance in Stroke and Cardiology around thrombolysis in 60 minutes and angioplasty door/call to balloon times were a combination of low volumes and clinical consideration and thus that processes were working well.

2. Alignment to 2020 Vision *[indicate with an 'X' which Plan this paper supports]*

Safety Plan	x	Public Health Plan	x	People Plan & Education Plan	X
Quality Plan	x	Research and Development		Estates Plan	
Financial Plan	x	Digital Plan		Other <i>[specify in the paper]</i>	

3. Previous consideration *[where has this paper been previously discussed?]*

WD5 Distribution to Groups, OMC, CLE, Q&S

4. Recommendation(s)

The Clinical Leadership Executive is asked to:

- Recognise** the Cancer performance success
- Note** the further work required on Sepsis and the administration around VTE and Readmissions

5. Impact *[indicate with an 'X' which governance initiatives this matter relates to and where shown elaborate]*

Trust Risk Register	x	Numerous				
Board Assurance Framework	x	SBAF 11: Labour Supply and SBAF 14: Amenable Mortality				
Equality Impact Assessment	Is this required?	Y		N	x	If 'Y' date completed
Quality Impact Assessment	Is this required?	Y		N	x	If 'Y' date completed